logo
  

EARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q3 Earnings Report

Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):

-Earnings: -$76.79 million in Q3 vs. -$43.99 million in the same period last year.
-EPS: -$0.91 in Q3 vs. -$0.58 in the same period last year.
-Analysts projected -$0.91 per share
-Revenue: $6.32 million in Q3 vs. $10.97 million in the same period last year.

For comments and feedback contact: editorial@rttnews.com

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT